RUNX2 and cancer: Noteworthy, the cancer lesions with higher value of SUV max (BM+ patients) (Figure 5) were characterized by the presence of calcium-phosphate calcifications and a higher number (>300) of RUNX2-positive (Figure 5) and RANKL-positive (Figure 5) prostate cancer cells.